Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: lumiliximab, Biogen Idec.

Janice M Reichert1

  • 1Tufts Center for the Study of Drug Development, 192 South Street, Suite 550, Boston, MA 02111, USA. janice.reichert@tufts.edu

Current Opinion in Molecular Therapeutics
|January 25, 2005
PubMed
Summary

Lumiliximab, an anti-CD23 antibody, is being developed to treat allergies by blocking immunoglobulin E (IgE) antibody production. This targeted therapy offers potential relief for individuals with allergic conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges.

Cell·2026
Same author

Antibodies to watch in 2026.

mAbs·2026
Same author

Innovative antibody therapeutic development in China compared with the USA and Europe.

Nature reviews. Drug discovery·2025
Same author

YAbS: The Antibody Society's antibody therapeutics database.

mAbs·2025
Same author

Antibodies to watch in 2025.

mAbs·2024
Same author

The present and future of bispecific antibodies for cancer therapy.

Nature reviews. Drug discovery·2024

Area of Science:

  • Immunology
  • Allergy Research
  • Biotechnology

Background:

  • Allergic conditions are characterized by the overproduction of immunoglobulin E (IgE) antibodies.
  • The CD23 receptor on B cells plays a crucial role in regulating IgE synthesis.

Purpose of the Study:

  • To evaluate lumiliximab, a novel chimeric antibody, for the potential treatment of allergic conditions.
  • To investigate the mechanism of action of lumiliximab in inhibiting IgE production.

Main Methods:

  • Development of lumiliximab, a primatized macaque/human chimeric antibody targeting CD23.
  • Preclinical studies to assess the efficacy of lumiliximab in inhibiting IgE antibody production.

Main Results:

  • Lumiliximab demonstrated inhibition of immunoglobulin E (IgE) antibody production.
  • The anti-CD23 antibody targets a key regulator of IgE synthesis.

Conclusions:

  • Lumiliximab shows promise as a therapeutic agent for allergic conditions.
  • Targeting the CD23 receptor offers a potential new strategy for managing allergies.

Related Experiment Videos